trial
as of 2026-07-01NST-SPARK Open-Label Phase 1 STTR (IGNITE)
NCTId NCT07593456
at a glance
— · Not Yet Recruiting
Enrollment 30 (estimated)
Sponsored by North Shore Therapeutics, Inc.
Primary completion 2028-02-28
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Not Yet Recruiting
Enrollment
30 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2027-03-01
Primary completion
2028-02-28
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
North Shore Therapeutics, Inc.Lead Sponsor
University of PennsylvaniaCollaborator
Investigators
3
Moein Foroughi, MDPrincipal Investigator
Christian Kohler, MDPrincipal Investigator
Dan Wolf, MDPrincipal Investigator
Sites
2 total
Glen Oaks, United StatesPhiladelphia, United States
Facts & assertions
4 sourced
Enrollment
30
Phase
NA
Primary Completion Date
2028-02-28
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
indication
indication
indication
indication
investigator